Lawsuit Filed Over Familial Dysautonomia Genetic Patent

Genetics

By Nadja Spiegelman

Published August 11, 2010, issue of August 20, 2010.
  • Print
  • Share Share

A lawsuit now working its way through federal court is adding an interesting twist to the heated debate over genetic patenting.

Two scientists from Fordham University are suing Massachusetts General Hospital over a patent on the gene that causes the rare Ashkenazi recessive genetic disorder familial dysautonomia. The two sides are each aligned with groups working to prevent and combat genetic disease in the Jewish community.

The Dysautonomia Foundation, whose board of directors consists primarily of parents of those afflicted with FD, funded the defendants’ research on the gene. It currently holds the license to the patent.

Dor Yeshorim, which provides confidential carrier screening in the Orthodox community, helped fund the plaintiffs’ research on the FD gene. It would presumably gain control over the license to the gene should the plaintiffs win in court.

While neither organization is named as a party to the lawsuit, both say that they want to hold the patent only to ensure freedom of access for those doing carrier testing and research.

“It’s a shame that the parties involved are spending money on legal costs when that money should be spent on funding research and testing,” said David Brenner, the Dysautonomia Foundation’s executive director.

Dor Yeshorim did not respond to requests for comment.

At the heart of this legal battle are two almost simultaneous applications for the genetic patent.

In the late 1990s, Dor Yeshorim, in association with Fordham University, funded the research of Berish Rubin and Sylvia Anderson. At the same time, the Familial Dysautonomia Foundation funded the research of James Gusella and Susan Slaugenhaupt at Massachusetts General Hospital.

In December of 2000, the Fordham researchers submitted an article to The American Journal of Human Genetics that detailed their findings on the gene’s sequence. They included with their manuscript a letter requesting that it not be sent for review to other researchers working in the field, specifically citing Gusella and Slaugenhaupt, among others. According to the plaintiffs, the journal nevertheless sent “the manuscript, or a summary of its critical aspects” to Gusella.

In a court filing, MGH said that Gusella had received, unsolicited, “a document that purported to be an abstract” of the article and that he did not review it. But MGH denied the plaintiffs’ claim that Gusella or his colleagues had incorporated elements from the article into their patent application.

Shortly before the article’s publication in January 2001, Gusella and Anderson applied for a patent on the FD gene. Soon after, Rubin and Anderson filed for the same patent. In 2008, after both claims went through the U.S. Patent and Trademark Office’s lengthy review process, the patent was awarded to MGH and Gusella and Anderson. MGH made the Dysautonomia Foundation the patent’s exclusive licensee.

In January 2009, Rubin and Anderson brought their lawsuit against MGH, claiming that the information in the patent was drawn from their then-unpublished article. A ruling is not expected before 2011.

Lawyers for sides in the case did not respond to requests seeking comment. The scientists involved in the dispute either declined to comment or did not respond to queries.

Currently, the Dysautonomia Foundation does not charge royalties to researchers studying the gene or to nonprofit organizations that wish to conduct carrier testing for the gene, according to Brenner. The foundation does, however, charge a nominal fee to two large commercial companies that provide carrier screening, with the resulting revenue channeled exclusively to FD research, he said.

“Our motivation is to cure our own children, and anybody who can do that, including these researchers at Fordham, we’d be very enthusiastic about them making progress,” Brenner said. “The reason we sought the patent was so that it would always be available to researchers — and to make sure that no other families would go through the same thing we’ve gone through.”

Dor Yeshorim has also maintained that its motives for seeking the patent are not profit-driven. “If Dr. Rubin wins, our organization and he will not charge anything for anyone to use the IP,” Dor Yeshorim spokesman Avrom Eliyahu wrote in a June 25 e-mail to Bloomberg news, using an abbreviation for “intellectual property.” Dor Yeshorim seeks control of the patent “only to stop anyone from charging for its use,” he wrote.

Dor Yeshorim has in the past signaled its opposition to genetic patenting. In a 2004 interview with New Scientist magazine, Dor Yeshorim’s founder and director, Rabbi Josef Ekstein, stated: “Patenting can threaten the entire genetic prevention system. Yes, a small royalty should be paid to companies or individuals who make the discovery. However, patenting can destroy all the advantages made from a discovery, and prevent developments from benefiting mankind.”


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • “This is a dangerous region, even for people who don’t live there and say, merely express the mildest of concern about the humanitarian tragedy of civilians who have nothing to do with the warring factions, only to catch a rash of *** (bleeped) from everyone who went to your bar mitzvah! Statute of limitations! Look, a $50 savings bond does not buy you a lifetime of criticism.”
  • That sound you hear? That's your childhood going up in smoke.
  • "My husband has been offered a terrific new job in a decent-sized Midwestern city. This is mostly great, except for the fact that we will have to leave our beloved NYC, where one can feel Jewish without trying very hard. He is half-Jewish and was raised with a fair amount of Judaism and respect for our tradition though ultimately he doesn’t feel Jewish in that Larry David sort of way like I do. So, he thinks I am nuts for hesitating to move to this new essentially Jew-less city. Oh, did I mention I am pregnant? Seesaw, this concern of mine is real, right? There is something to being surrounded by Jews, no? What should we do?"
  • "Orwell described the cliches of politics as 'packets of aspirin ready at the elbow.' Israel's 'right to defense' is a harder narcotic."
  • From Gene Simmons to Pink — Meet the Jews who rock:
  • The images, which have since been deleted, were captioned: “Israel is the last frontier of the free world."
  • As J Street backs Israel's operation in Gaza, does it risk losing grassroots support?
  • What Thomas Aquinas might say about #Hamas' tunnels:
  • The Jewish bachelorette has spoken.
  • "When it comes to Brenda Turtle, I ask you: What do you expect of a woman repressed all her life who suddenly finds herself free to explore? We can sit and pass judgment, especially when many of us just simply “got over” own sexual repression. But we are obliged to at least acknowledge that this problem is very, very real, and that complete gender segregation breeds sexual repression and unhealthy attitudes toward female sexuality."
  • "Everybody is proud of the resistance. No matter how many people, including myself, disapprove of or even hate Hamas and its ideology, every single person in Gaza is proud of the resistance." Part 2 of Walid Abuzaid's on-the-ground account of life in #Gaza:
  • After years in storage, Toronto’s iconic red-and-white "Sam the Record Man" sign, complete with spinning discs, will return to public view near its original downtown perch. The sign came to symbolize one of Canada’s most storied and successful Jewish family businesses.
  • Is $4,000 too much to ask for a non-member to be buried in a synagogue cemetery?
  • "Let’s not fall into the simplistic us/them dichotomy of 'we were just minding our business when they started firing rockets at us.' We were not just minding our business. We were building settlements, manning checkpoints, and filling jails." What do you think?
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.